Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486102 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT07486102 is a Phase 1 study that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 44 participants.
The verdict
NCT07486102, a Phase 1 study, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study is open to healthy people and people with liver problems. Adults between 18 and 80 years can participate. The purpose of this study is to compare how a medicine called BI 3000202 is handled by the body in people with and without liver problems. All participants take 1 tablet of BI 3000202. Participants with liver problems may also continue their regular treatment for their liver condition. Participants are in the study for about 1 month. During this time, participants visit the study site about 11 times. Where possible, some of these visits may happen by phone. For some visits, participants stay at the study site overnight. Doctors regularly test the amount of BI 3000202 in the blood and check for any health problems.
Interventions
- DRUG BI 3000202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07486102
The ClinicalTrials.gov registry entry for NCT07486102 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 3000202 is the first listed.
NCT07486102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07486102 about?
NCT07486102 is a clinical study titled "A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems". This study is open to healthy people and people with liver problems. Adults between 18 and 80 years can participate. The purpose of this study is to compare how a medicine called BI 3000202 is handled by the body in people with and without liver problems. All participants take 1 tablet of BI 300020...
What is the current status of trial NCT07486102?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2026-05-01. Estimated completion is 2027-02-27.
What interventions are being tested in trial NCT07486102?
The interventions under investigation include: BI 3000202 (DRUG).
Who is sponsoring clinical trial NCT07486102?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.